Introduction
PTEN is a tumor suppressor gene on human chromosome 10q23 that is deleted or mutated in about 20 ± 40% of glioblastomas but rarely altered in low-grade gliomas (Duerr et al., 1998; Wang et al., 1997) . PTEN contains the motif of protein tyrosine phophatases and functions to dephosphorylate both phophotyrosyl and phosphoseryl/threonyl residues and phosphoinositols phosphorylated on the 3' position of the inositol ring (Li and Sun, 1997; Maehama and Dixon, 1998; Myers et al., 1997) . Expression of wild-type PTEN cDNA supresses proliferation in glioma cells with mutant endogenous PTEN alleles but not in glioma cells with a wild-type PTEN background (Furnari et al., 1997) . Further, adenovirus-mediated MMAC1/PTEN gene transfer suppresses tumorigenicity of U87MG glioblastoma cells in vivo (Cheney et al., 1998) . PTEN has similarity to the cytoskeletal protein tensin. Exogenous expression of PTEN in ®broblasts and a glioma cell line with mutant PTEN alleles results in decreased migration by virtue of decreased integrin-mediated cell spreading and the formation of focal adhesions. These inhibitory properties of PTEN depend on an intact phosphatase domain (Tamura et al., 1998) .
Malignant glioma cells show marked resistance to multiple apoptotic stimuli including radiochemotherapy. We have recently correlated the responses of a panel of 12 glioma cell lines to various chemotherapeutic drugs with the dierential expression of BCL-2 family proteins and their status of p53, p21, MDM-2, p16, CDK-4 and RB . Unexpectedly, no molecular predictor of response to chemotherapy was identi®ed. Therefore, other candidate molecules for the regulation of radiochemosensitivity need to be examined. Here, we investigated the eect of PTEN gene transfer in the response of four human glioma cells with dierent endogenous PTEN gene status to dierent cancer chemotherapy drugs, to irradiation, and to apoptosis induced by the cytotoxic cytokine, CD95L.
Results

PTEN gene transfer induces growth suppression but not apoptosis in glioma cell lines
PTEN mutations in a set of glioma cell lines have recently been characterized (Furnari et al., 1997) . Here, we sought to examine the eect of ectopic PTEN expression on the sensitivity of glioma cells to chemotherapeutics, irradiation or CD95L. We introduced exogenous PTEN genes into four glioma cell lines. LN-18 and LN-229 are wild-type for PTEN and show PTEN protein expression on immunoblots ( Figure 1a ). U87MG and LN-308 harbor dierent mutations of the PTEN gene (Furnari et al., 1997) . U87MG cells, which carry a deletion of codons 55 ± 70 (exon 3) within the tension/auxilin homology region, display a slightly smaller endogenous PTEN protein signal and a correspondingly broader band when full length PTEN alleles are exogenously expressed ( Figure  1a) . Expression of the ectopic PTEN alleles was veri®ed by immunoblotting for the HA-tag ( Figure  1b ). Parental and control-transfected LN-308 cells do not show a band corresponding to PTEN due to a G129R (striped bars) was assessed as described in Materials and methods. Results are normalized with the vector controls set to 100% (n=3, *P50.05, t-test). (d) DNA fragmentation of glioma cells transfected with empty vector (mock), or PTEN, or PTEN G129R was assessed by DNA¯uorometry as described previously (Roth et al., 1997) . As a positive control, non-transfected parental cells were treated with VM26 (25 mM) for 72 h. Data are expressed as mean percentages and SEM of three independent experiments done in triplicate truncating mutation in the PTEN gene (Figure 1a, LN (Figure 1c ). To dierentiate whether the observed eects were due to growth suppression or induction of apoptosis in the wild-type PTEN-transfected U87MG and LN-308 cells, we determined the degree of DNA fragmentation after mock transfection or expression of wild-type PTEN or PTEN G129R . There was no increase levels of DNA fragmention above baseline after transfection with either plasmid. In contrast, as a positive control, treatment with teniposide (VM26) resulted in a DNA fragmentation of up to 23% (Figure 1d ).
Ectopic PTEN expression does not alter glioma cell sensitivity to chemotherapeutics but enhances radiosensitivity and CD95L-induced apoptosis Next, we asked whether PTEN may play a role in regulating the chemosensitivity of malignant glioma cell lines. We assessed the modulation by the PTEN status of the cytotoxic and antiproliferative eects of ®ve dierent chemotherapeutics, vincristine, cytarabine, (VM26), cisplatin and BCNU. Neither transfec- tion with PTEN-HA nor with the mutant allele nor with the pBP control vector resulted in an altered response of any of the cell lines to any of the drugs, as assessed at the level of the EC 50 values for growth inhibition in 72 h continous exposure assays. As an example, the data for vincristine are shown in Figure  2 (left panel). Further, we pooled our previously published data on the endogenous PTEN status of 12 human glioma cell lines (Furnari et al., 1997) with their sensitivity to ®ve dierent cancer chemotherapy drugs and determined that there is no dierence in the EC 50 value for either BCNU, vincristine, cytarabine, teniposide (VM26), and cisplatin in acute cytotoxicity assays between PTEN-wildtype and PTEN-mutant glioma cell lines (data not shown).
In contrast, ectopic expression of wild-type PTEN in cell lines mutant for PTEN (U87MG, LN-308) resulted in a strong sensitization to irradiation, notably in the clinically relevant dose range of 1 ± 2 Gy (Figure 2 , middle panel). The dose of irradiation required to reduce the cell counts to 37% was lowered by wild-type PTEN from 3.9 to 1.2 Gy in U87MG cells and from 4.5 to 0.8 Gy in LN308 cells. This eect was speci®c in that wild-type PTEN gene transfer did not alter the sensitivity to irradiation in PTEN wild-type cell lines and in that the PTEN G129R mutant failed to alter the radiosensitivity of any of the four cell lines.
Next, we treated the glioma cells with CD95L and cycloheximide (CHX), a protein synthesis inhibitor that facilitates CD95L-induced apoptosis (Weller et al., 1994) . Interestingly, U87MG and LN-308 glioma cells forced to express wild-type PTEN showed a strong increase of apoptosis compared with vector controls or PTEN G129R -expressing cells (Figure 2 , right panel). The EC 50 values for CD95L-induced apoptosis were shifted by wild-type PTEN from 70 U/ml to 20 U/ml in U87MG cells and from 4130 U/ml to 40 U/ml in LN-308 cells. Similar to the results for irradiation shown in Figure 2 , wild-type PTEN did not alter the sensitivity of LN-18 and LN-229 to CD95L, and mutant PTEN G129R had no eect on CD95L-induced apoptosis.
To evaluate whether the augmentation of CD95L-induced apoptosis was due to facilitation of apoptosis upstream or downstream of caspase 3 activation, we transfected the cell lines with the various PTEN vectors and the determined the caspase 3 activity evoked by CD95L/CHX exposure. Figure 3 shows that there was signi®cantly more caspase 3 activity in response to CD95L/CHX treatment in wild-type PTEN-transfected U87MG and LN-308 cells than in PTEN G129R -transfected cells or vector control cells, suggesting that PTEN facilitates the CD95 signaling cascade upstream of caspase 3 activation.
Wild-type PTEN mediates dephosphorylation of PKB in PTEN-mutant glioma cells
Given the phosphatase activity of PTEN, we next asked whether the observed facilitation of radiationand CD95L-induced apoptosis in U87MG and LN-308 cells was linked to the dephosphorylation of speci®c molecules. PKB, a serine/threonine protein kinase, has been shown to inhibit CD95L-mediated apoptosis in COS7 cells (HaÈ usler et al., 1998) . Further several growth factors like PDGF, EGF or IGF-1 convert PKB from an inactive to an active form in neuronal cells by phosphorylation (Dudek et al., 1997) . Therefore, we stimulated mock-or PTENtransfected U87MG and LN-229 cells with control medium or IGF-1 (25 ng/ml) for 10 min under serumfree conditions, performed immunoprecipitation from whole cell lysates using an anti-PKB antibody, and subjected the lysates to SDS ± PAGE and antiphosphothreonine immunoblotting. Immunoblotting for total PKB protein levels was done in parallel. PKB was expressed in both cell lines, irrespective of endogenous or exogenous PTEN status (Figure 4a) . Further, the levels of PKB protein were unaected by IGF-1.
Next, we examined the state of threonine phosphorylation in both cell lines, depending on the expressed transgene and on the absence or presence of IGF-1. Interestingly, ectopic expression of wild-type PTEN resulted in a loss of phophorylated PKB in U87MG. No such eect was seen with PTEN G129R in U87MG cells, and no modulation of PKB phosphorylation was in LN-229 cells with either plasmid. However, IGF-1 did not alter the amounts of phosphorylated PKB under any of these conditions (Figure 4b ). Given the failure of IGF-1 to prevent the dephosphorylation of PKB by PTEN, we expected that IGF-1 would also fail to modulate the biological eects of PTEN. This, however, was not the case. As shown in Figure 5 (lower panel), IGF completely prevented the PTENmediated sensitization of apoptosis in U87MG cells, without altering induction of apoptosis in mocktransfected U87MG cells or PTEN-transfected LN-229 cells. To determine whether this eect was mediated through PI 3-kinase, we co-exposed the cells to an inhibitor of PI 3-kinase, wortmannin (100 nM), and IGF-1. Wortmannin eliminated the eect of IGF-1 on U87MG expressing wild-type PTEN ( Figure 5 , lower panel), indicating a role for PI 3-kinase in IGF-1 signaling. There was no eect of wortmannin on CD95L-induced apoptosis in the other sublines ( Figure 5 ). G129R (striped bars) and exposed to CD95L (LN-18, U87MG, LN-229: 30 U/ml; LN-308: 80 U/ml) plus cycloheximide (10 mg/ml). Caspase 3 activity was assessed by DEVD ± AMC cleavage after 6 h. Data are expressed as OD ratios relative to untreated controls. Thus, a value of 1 would indicate the lack of caspase activation in response to a given stimulus PTEN sensitizes to CD95L-induced apoptosis W Wick et al Figure 2a . IGF (25 ng/ml) was added (®lled symbols) or not added (open symbols) 10 min prior to CD95L/CHX treatment. Further, 10 min before CD95L/CHX was administered, wortmannin (100 nM) was added (squares) or not added (circles). Experiments were repeated at least three times in triplicate and results are expressed as mean percentages of survival (s.e.m.510%) Discussion PTEN is a mutational target in a variety of human glioma, breast, prostate, melanoma and kidney tumor specimens or cell lines (Liu et al., 1997; Rhei et al., 1997; Teng et al., 1997) . PTEN has features of a protein tyrosine phophatase which dephosphorylates both phophotyrosyl and phosphoseryl/threonyl residues (Li and Sun, 1997) . Expression of wild-type PTEN in glioma cells lacking wild-type PTEN function results in growth suppression (Furnari et al., 1997) and inhibition of migration, spreading and focal adhesion formation (Tamura et al., 1998) .
In the present study, we transferred mutant or wildtype PTEN alleles into glioma cell lines with mutant (U87MG, LN-308) or wild-type (LN-18, LN-229) PTEN alleles and observed the growth inhibitory eect of wild-type PTEN in PTEN-mutant cells. Expression of the mutant form of PTEN did not interfere with cell growth, indicating that this mutant was not functional in this paradigm and that there was no dominant-inhibitory activity towards wild-type PTEN activity. Next, we monitored the modulation of chemosensitivity and sensitivity to radiotherapy and CD95L-induced apoptosis. We found that the sensitivity to vincristine, cytarabine, VM26, cisplatin and BCNU was virtually unaltered by wild-type PTEN in all four cell lines, irrespective of their PTEN status. Further, a correlation of the endogenous PTEN status of 12 human glioma cell lines (data from: Furnari et al. (1997) ) with their sensitivity to seven dierent cancer chemotherapy drugs, including BCNU, vincristine, cytarabine, VM26, doxorubicin, camptothecin and blapachone (data from: Weller et al., (1998) ) revealed no correlation between PTEN and chemosensitivity.
In contrast, irradiation-induced cell death was signi®cantly enhanced by wild-type PTEN gene transfer in glioma cell lines lacking wild-type PTEN (U87MG, LN-308) but not in cell lines retaining wildtype PTEN (Figure 2, middle panel) . The phosphatase domain was required for radiosensitization since the PTEN G129R mutant had no such eect. We have previously characterized CD95L-induced apoptosis as a novel approach of immunochemotherapy to malignant glioma (Roth et al., 1997; Weller et al., 1994) . Here, we showed that wild-type PTEN speci®cally sensitized the PTEN-mutant glioma cell lines, U87MG and LN-308), to CD95L-induced apoptosis (Figure 2 ). This sensitization operated upstream of caspase 3 activation (Figure 3 ). These observations led us to compare data on PTEN status, CD95 expression and sensitivity to CD95L in an extended series of glioma cell lines (Table 1) . A comparison of the three wild-type PTEN cell lines, LN-18, LN-229, and LN-428, with the eight PTEN mutant cell lines showed that lower levels of CD95 expression were more likely to transmit a death signal when PTEN is wild-type than with mutant PTEN. This was particularly true for the cell lines U138MG, LN-319 and U373MG which were rather resistant to CD95L despite strong CD95 expression.
Activation of PI 3-kinase has recently been shown to inhibit CD95L-induced apoptosis in COS7 cells (HaÈ usler et al., 1998) . This eect was hypothesized to be mediated by PKB, a serine/threonine protein kinase that is phophorylated at two major sites, Thr308 in the kinase domain and Ser473 in the carboxy-terminus, and activated thereby (Downward, 1998) . PKB provides a survival signal that protects cells from apoptosis induced by various stresses, and the gene has been shown to be ampli®ed in many human tumors (Marte and Downward, 1997) . Recently, it has been shown that PTEN acts as phosphoinositide 3-phosphatase that regulates phosphatidylinositol 3,4,5 triphosphate, PI(3,4,5)P 3 , levels (Maehama and Dixon, 1998) . PI(3,4,5)P 3 in turn has been shown to directly activate PKB by Thr308 phosphorylation. PKB may act via the p70 S6 kinase to inhibit glycogen synthase kinase-3, the BCL-2-related BAD protein, and other proteins (Marte and Downward, 1997; Crowder and Freeman, 1998; Downward, 1998; Dudek et al., 1997) . Thus, PKB is a potential downstream target of PI(3,4,5)P 3 .
Both PTEN-mutant U87MG cells and PTEN-wildtype LN-229 cells expressed the PKB protein ( Figure  3a) . Both cell lines contained signi®cant amounts of phosphorylated (active) PKB. The transfer of mutant or wild-type PTEN alleles into U87MG or LN-229 cells did not alter the levels of PKB protein. However, expression of wild-type PTEN in PTEN mutant U87MG resulted in a striking loss of phosphorylated PKB, suggesting that intact PTEN can dephosphorylate PKB on threonine residues and that loss of PTEN activity resulted in a constitutive activation of PKB. Reversal of this phenotype promoted enhanced sensitivity to CD95L-induced apoptosis (Figures 2 and  3) . Interestingly, the presence of phosphorylated PKB in untransfected PTEN wild-type LN-229 cells suggested that there were as yet unde®ned pathways to escape from the PTEN-mediated dephosphorylation of PKB in glioma cells.
In growth factor dependent paradigms of cell survival, PKB is activated through PI 3-kinase (Crowder and Freeman, 1998) . IGF/IGF-receptor interaction is one physiological trigger of PKB activation through PI 3-kinase in a variety of cells. We found that IGF abrogated the PTEN-mediated sensitization of glioma cells towards CD95L-induced apoptosis. This action was blocked by wortmannin, suggesting that PI 3-kinase was required for the eect The table summarizes data from previously published studies (Furnari et al. 1997; Rieger et al. 1998) : PTEN status, CD95 expression expressed as speci®c¯uorescence indexes determined by ratios of¯uorescences obtained with speci®c CD95 antibody versus control antibody, and survival after a 16 h exposure to CD95L alone (100 U/ml) or CD95L (10 U/ml) plus cycloheximide (10 mg/ml), expressed as mean percentages of survival and s.e.m. (n=3) of IGF. Since IGF exerted its eect without preventing the dephosphorylation induced by PTEN, PKB phosphorylation may be dispensable for the cytoprotective eect of IGF in this paradigm. Thus, antagonism of speci®c actions of wild-type PTEN which promote stimulus-evoked apoptosis in glioma cells might underlie some of eects in the cancerogenesis of gliomas attributed to IGF (Baserga, 1995) .
Materials and methods
Cell lines
The glioma cell lines used in this study have been described in previous studies . Their PTEN status has been characterized (Furnari et al., 1997) .
Transfections
Transfections were performed using the calcium phosphate technique. Brie¯y, 10 mg of control pBP (pBP), of mutant PTEN G129R -HA (PTEN G129R ), or of pBP-PTEN-HA (PTEN) (Furnari et al., 1997) were used per 100 mm dish containing cells seeded at 7610 5 cells per dish 24 h before transfection. Transfections were terminated at 6 h by rinsing the cells with PBS and supplementing serum-containing medium. At 24 h post transfection, the cells were split at 1 : 3 dilution and maintained for 7 days in puromycin-containing medium (500 ng/ml) at 2% fetal calf serum.
Immunoblot analysis and immunoprecipitation
Immunodetection of the HA-tagged PTEN was done as described previously (Furnari et al., 1997) with an anti-HA antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and chemiluminescence (Amersham, Braunschweig, Germany). For detection of PTEN protein, an anti-PTEN antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used.
Immunoprecipitation
PKB was detected using cell lysates prepared in the presence of a phosphatase inhibitor (sodium vanadate, Na 3 VO 4 , 10 mM), titrated acidic (yellow) with 3 M HCl) with standard lysis buer. Immunoprecipitation was started by adding a-PKB antibody (PKB/Akt-1, Santa Cruz) (2 ± 4 mg/sample) and incubating the reaction for at 4 h at 48C. According to standard protocols (Santa Cruz Biotechnology 6/1996), protein A/G coupled agarose was added, followed by another 1 ± 3 h of incubation at 48C. The precipitate was centrifuged at 6000 ± 8000 r.p.m. and washed carefully six times with sodium vanadate-enriched lysis buer. Laemmli buer was added and proteins seperated by standard SDS ± PAGE. Immunoblotting was done with a monoclonal anti-phosphothreonine antibody (Santa Cruz) for the detection of threonine phosphorylation. In parallel, an aliquot of the same sample was probed with the anti-PKB antibody to verify precipitation as above. Detection was done using chemiluminescence (Amersham, Braunschweig, Germany).
Viability and apoptosis studies
Cell growth and survival were assessed by crystal violet staining . Proliferation was assessed after transfection and selection with puromycin by counting of viable cells after 7 days. Results were normalized in terms of percentage of vector transfection with the vector control set 100% in each case (Furnari et al., 1997) . CD95L-containing supernatant was obtained from murine CD95L-transfected N2A murine neuroblastoma cells (Roth et al., 1997) . Apoptotic cell death was assessed morphologically and measured by quantitative assessment of DNA fragmentation . All experiments were performed in 2% fetal calf serum containing medium, except for the survival studies with IGF-1. In the studies serum free media were applied before adding the growth factor.
Biochemical studies
Caspase 3 activity was measured by conversion of thē uorescent substrate, DEVD ± AMC (Schulz et al., 1997) .
Statistical analysis
All experiments were performed in triplicate and repeated at least once. Data from representative experiments are presented and expressed as means and SEM. Signi®cance was calculated using the unpaired t-test.
Abbreviations CD95 ligand, CD95L; epidermal growth factor, EGF; insulin-like growth factor-1 IGF-1; pBP-PTEN-HA, PTEN; protein kinase B, PKB, phosphatidylinositol 3,4,5-trisphosphate, PI (3,4,5)P 3 : phosphatidylinositol 4,5-bisphosphate, PI(4,5)P 2 ; phosphoinositide 3-OH kinase, PI 3-kinase; platelet derived growth factor PDGF; PTEN G129R -HA, PTEN G129R , wortmannin (WM).
